At a glance
The Emergent Drug Panel (EDP) kits include reference materials that support laboratory screening for additional emerging drugs of abuse that may be found in fentanyl-containing samples.
EDP, EDP-Version 1 (EDP-V1), and EDP-Internal Standard (EDP-IS) Kits
The EDP and EDP-V1 Kits contain reference materials that support laboratory screening for 80 emergent synthetic opioids, benzodiazepines, stimulants, hallucinogens, synthetic cannabinoids, and xylazine. The new EDP-Internal Standard (EDP-IS) kit contains 24 isotopically labeled internal standards corresponding to the most prevalent compounds contained in the EDP and FAS Kit panels.
Compounds in the EDP, EDP-V1, and EDP-IS Kits
Additional product information
- EDP and EDP-V1 Kits include 200 micrograms of each compound
- The EDP-IS Kit includes 200 micrograms of each isotopically labeled compound in a 2 mg/mL solution
- Includes the most prevalent compounds identified on Drug Enforcement Administration (DEA) Emerging Threat Reports and The Center for Forensic Science Research and Education (CFSRE) Scope and Trend Reports (2019-2022)
- Improves immunoassay and mass spectrometry screening methods
Safety Data Sheets, Certificates of Analyses, and Other Product-Specific Documents
Request the EDP, EDP-V1, and EDP-IS Kits
Laboratories are asked to acknowledge the use of the Traceable Opioid Material® Kits in presentations, publications, reports, and other communications by using the following citation: "Laboratory findings were made possible, in part, by the Centers for Disease Control and Prevention's design and support of Traceable Opioid Material® Kits."